deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02639182

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Metastatic Renal Cell Carcinoma
Interventions AGS-16C3F Axitinib
Updated 21 times since 2017 Last updated: Oct 30, 2024 Started: May 3, 2016 Primary completion: Oct 2, 2020 Completion: Oct 2, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Renal Cell Carcinoma, this trial is completed. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 21 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Apr 2018 · 10 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshot

Change History

21 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Dec 2021 — Jan 2022 [monthly]

    Completed PHASE2

  2. Jun 2021 — Dec 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  6. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  9. May 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  13. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

  15. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Global Development, Inc.
Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Calgary, Canada , Charleston, United States , Detroit, United States , Durham, United States , Edmonton, Canada and 15 more locations